{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:47:16Z","timestamp":1793011636206,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40265-021-01486-1","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T07:03:14Z","timestamp":1615791794000},"page":"635-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Fabry Disease: The Current Treatment Landscape"],"prefix":"10.1007","volume":"81","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"key":"1486_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet."},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30:1397\u2013405.","journal-title":"Hum Mutat."},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184\u201392.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet."},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab."},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124:189\u2013203.","journal-title":"Mol Genet Metab."},{"key":"1486_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM197307052890103","volume":"289","author":"RO Brady","year":"1973","unstructured":"Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, et al. Replacement therapy for inherited enzyme deficiency. N Engl J Med. 1973;289:9\u201314.","journal-title":"N Engl J Med."},{"key":"1486_CR9","first-page":"393","volume":"16","author":"RJ Desnick","year":"1980","unstructured":"Desnick RJ, Dean KJ, Grabowski GA, Bishop DF, Sweeley CC. Enzyme therapy XVII: Metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease. Birth Defects Orig Artic Ser. 1980;16:393\u2013413.","journal-title":"Birth Defects Orig Artic Ser."},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med."},{"key":"1486_CR11","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"1486_CR12","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2265\u201378.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"T Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C, Sch\u00f6nfeld D, Banikazemi M, Hopkin RJ, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010;12:703\u201312.","journal-title":"Genet Med."},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","volume":"103","author":"DA Hughes","year":"2011","unstructured":"Hughes DA, Barba Romero M\u00c1, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2013the Fabry Outcome Survey. Mol Genet Metab. 2011;103:207\u201314.","journal-title":"Mol Genet Metab."},{"key":"1486_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77\u201386.","journal-title":"Ann Intern Med."},{"key":"1486_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-K\u00fchl S, Sommer C, et al. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11:88. https:\/\/doi.org\/10.1186\/s13023-016-0473-4.","journal-title":"Orphanet J Rare Dis."},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, St\u00f6rk S, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524\u20139.","journal-title":"Circulation"},{"key":"1486_CR18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/gim.2013.53","volume":"15","author":"DP Germain","year":"2013","unstructured":"Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry Registry. Genet Med. 2013;15:958\u201365.","journal-title":"Genet Med."},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27:1042\u20139.","journal-title":"Nephrol Dial Transplant."},{"key":"1486_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet."},{"key":"1486_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","volume":"126","author":"DP Germain","year":"2019","unstructured":"Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126:224\u201335.","journal-title":"Mol Genet Metab."},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125. https:\/\/doi.org\/10.1186\/s13023-015-0338-2.","journal-title":"Orphanet J Rare Dis."},{"key":"1486_CR23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","volume":"38","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis. 2015;38:1129\u201336.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137\u201348.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1681\/ASN.2013060585","volume":"25","author":"F Weidemann","year":"2014","unstructured":"Weidemann F, Kr\u00e4mer J, Duning T, Lenders M, Canaan-K\u00fchl S, Krebs A. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25:837\u201349.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1681\/ASN.2015030337","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Canaan-K\u00fchl S, Kr\u00e4mer J, Duning T, Reiermann S, Sommer C, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch - 2-year follow-up. J Am Soc Nephrol. 2016;27:952\u201362.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR27","first-page":"807","volume":"32","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, T\u00f8ndel C. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol Dial Transplant. 2017;32:807\u201313.","journal-title":"Nephrol Dial Transplant."},{"key":"1486_CR28","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","volume":"33","author":"J Kr\u00e4mer","year":"2018","unstructured":"Kr\u00e4mer J, Lenders M, Canaan-K\u00fchl S, Nordbeck P, \u00dc\u00e7eyler N, Blaschke D, et al. Fabry disease under enzyme replacement therapy - new insights in efficacy of different dosages. Nephrol Dial Transplant. 2018;33:1362\u201372.","journal-title":"Nephrol Dial Transplant."},{"key":"1486_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int."},{"key":"1486_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR31","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, Foell D, Brand E. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol. 2018;141:2289\u201392.","journal-title":"J Allergy Clin Immunol."},{"key":"1486_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jimd.12176","volume":"43","author":"F Stappers","year":"2020","unstructured":"Stappers F, Scharnetzki D, Schmitz B, Manikowski D, Brand SM, Grobe K, et al. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43:334\u201347.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR33","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, Nordbeck P, Canaan-K\u00fchl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, Canaan-K\u00fchl S, Arash-Kaps L, Drechsler C, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282:241\u201353.","journal-title":"J Intern Med."},{"key":"1486_CR35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/BF00484919","volume":"13","author":"G Romeo","year":"1975","unstructured":"Romeo G, D\u2019Urso M, Pisacane A, Blum E, De Falco A, Ruffilli A. Residual activity of alpha-galactosidase A in Fabry\u2019s disease. Biochem Genet. 1975;13:615\u201328.","journal-title":"Biochem Genet."},{"key":"1486_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1096\/fj.04-2375com","volume":"19","author":"GH Yam","year":"2005","unstructured":"Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J. 2005;19:12\u20138.","journal-title":"FASEB J."},{"key":"1486_CR37","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1021\/jm301557k","volume":"56","author":"RE Boyd","year":"2013","unstructured":"Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA, et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem. 2013;56:2705\u201325.","journal-title":"J Med Chem."},{"key":"1486_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112\u20135.","journal-title":"Nat Med"},{"key":"1486_CR39","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","volume":"267","author":"N Asano","year":"2000","unstructured":"Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, et al. In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000;267:4179\u201386.","journal-title":"Eur J Biochem."},{"key":"1486_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: A review in Fabry disease. Drugs. 2019;79:543\u201354.","journal-title":"Drugs"},{"key":"1486_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430\u20138.","journal-title":"Genet Med."},{"key":"1486_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med."},{"key":"1486_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288\u201396.","journal-title":"J Med Genet."},{"key":"1486_CR44","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J M\u00fcntze","year":"2019","unstructured":"M\u00fcntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, et al. Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther. 2019;105:1224\u201333.","journal-title":"Clin Pharmacol Ther."},{"key":"1486_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41431-020-0677-x","volume":"9","author":"E Riccio","year":"2020","unstructured":"Riccio E, Zanfardino M, Ferreri L, Santoro C, Cocozza S, Capuano I, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020;9:1. https:\/\/doi.org\/10.1038\/s41431-020-0677-x (Epub ahead of print. PMID: 32647377).","journal-title":"Eur J Hum Genet."},{"key":"1486_CR46","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.1832","volume":"108","author":"M Lenders","year":"2020","unstructured":"Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, et al. Treatment of Fabry disease with migalastat - outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther. 2020;108:326\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"1486_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.07.007","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020. https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.007 (Epub ahead of print. PMID: 33012654).","journal-title":"Mol Genet Metab."},{"key":"1486_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","volume":"56","author":"M Lenders","year":"2019","unstructured":"Lenders M, Stappers F, Niemietz C, Schmitz B, Boutin M, Ballmaier PJ, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56:548\u201356.","journal-title":"J Med Genet."},{"key":"1486_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, et al. Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114:259\u201367.","journal-title":"Mol Genet Metab."},{"key":"1486_CR50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42:534\u201344.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR51","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, Shulman A, Kizhner T, Azulay Y, Nataf Y, Tekoah Y, et al. Development and analytical characterization of pegunigalsidase alfa, a chemically cross-linked plant recombinant human \u03b1-galactosidase-A for treatment of Fabry disease. Bioconjug Chem. 2018;29:1630\u20139.","journal-title":"Bioconjug Chem."},{"key":"1486_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","volume":"39","author":"JS Shen","year":"2016","unstructured":"Shen JS, Busch A, Day TS, Meng XL, Yu CI, Dabrowska-Schlepp P, et al. Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis. 2016;39:293\u2013303.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jimd.12052","volume":"42","author":"JB Hennermann","year":"2019","unstructured":"Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. J Inherit Metab Dis. 2019;42:527\u201333.","journal-title":"J Inherit Metab Dis."},{"key":"1486_CR54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med. 2015;21:389\u201399.","journal-title":"Mol Med."},{"key":"1486_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford RWD, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103:703\u201311.","journal-title":"Clin Pharmacol Ther."},{"key":"1486_CR56","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160402","author":"G Brogden","year":"2017","unstructured":"Brogden G, Shammas H, Maalouf K, Naim SL, Wetzel G, Amiri M, et al. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro. 2017. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20160402."},{"key":"1486_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral Venglustat in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10:86\u201398.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1486_CR58","first-page":"S77","volume":"129","author":"DA Hughes","year":"2019","unstructured":"Hughes DA, Goker-Alpan O, Ganesh J, et al. A phase I\/II multicenter gene therapy clinical study for Fabry disease. Mol Genet Metab. 2019;129:S77.","journal-title":"Mol Genet Metab."},{"key":"1486_CR59","first-page":"S77","volume":"129","author":"DA Hughes","year":"2019","unstructured":"Hughes DA, Patel N, Kinch R, et al. First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry disease. Mol Genet Metab. 2019;129:S77-78.","journal-title":"Mol Genet Metab."},{"key":"1486_CR60","first-page":"430","volume-title":"Nelson textbook of pediatrics, vol. 1","author":"LK Zeltzer","year":"2015","unstructured":"Zeltzer LK, Palermo T, Krane E. Ch. 62 Pain management. In: Kliegman R, Stanton B, S. Geme J, Schor N, editors. Nelson textbook of pediatrics, vol. 1. 20th ed. Philadelphia: Elsevier Inc; 2015. p. 430\u201346.","edition":"20"},{"key":"1486_CR61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373.","journal-title":"Lancet Neurol."},{"key":"1486_CR62","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanp\u00e4\u00e4 M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88.","journal-title":"Eur J Neurol."},{"key":"1486_CR63","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22:568\u201376.","journal-title":"CNS Neurosci Ther."},{"key":"1486_CR64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","volume":"19","author":"D Moulin","year":"2014","unstructured":"Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328\u201335.","journal-title":"Pain Res Manag."},{"key":"1486_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52:860\u20136.","journal-title":"J Med Genet."},{"key":"1486_CR66","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/ki.1997.394","volume":"52","author":"JM De'Oliveira","year":"1997","unstructured":"De\u2019Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 1997;52:771\u20137.","journal-title":"Kidney Int."},{"key":"1486_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2012","unstructured":"Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23:165\u201373.","journal-title":"J Am Soc Nephrol."},{"key":"1486_CR68","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2019","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2019;5:407\u201313.","journal-title":"Kidney Int Rep."},{"key":"1486_CR69","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00006231-199809000-00009","volume":"19","author":"CE Argoff","year":"1998","unstructured":"Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry\u2019s disease: response to metoclopramide. Nucl Med Commun. 1998;19:887\u201391.","journal-title":"Nucl Med Commun."},{"key":"1486_CR70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.dld.2018.02.011","volume":"50","author":"MJ Hilz","year":"2018","unstructured":"Hilz MJ, Arbustini E, Dagna L, Gasbarrini A, Goizet C, Lacombe D, et al. Non-specific gastrointestinal features: could it be Fabry disease? Dig Liver Dis. 2018;50:429\u201337.","journal-title":"Dig Liver Dis."},{"key":"1486_CR71","first-page":"148","volume":"44","author":"IE Danhof","year":"1974","unstructured":"Danhof IE, Stavola JJ. Accelerated transit of intestinal gas with simethicone. Obstet Gynecol. 1974;44:148\u201354.","journal-title":"Obstet Gynecol."},{"key":"1486_CR72","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000200726","volume":"49","author":"H Friis","year":"1991","unstructured":"Friis H, Bod\u2019e S, Rumessen JJ. Effect of simethicone on lactulose-induced H2 production and gastrointestinal symptoms. Digestion. 1991;49:227\u201330.","journal-title":"Digestion"},{"key":"1486_CR73","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14656566.2018.1494728","volume":"19","author":"G Bassotti","year":"2018","unstructured":"Bassotti G, Usai-Satta P, Bellini M. Linaclotide for the treatment of chronic constipation. Expert Opin Pharmacother. 2018;19:1261\u20136.","journal-title":"Expert Opin Pharmacother."},{"key":"1486_CR74","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/jgh.14086","volume":"33","author":"Y Yang","year":"2018","unstructured":"Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, et al. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol. 2018;33:980\u20139.","journal-title":"J Gastroenterol Hepatol."},{"key":"1486_CR75","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1053\/j.gastro.2020.06.007","volume":"159","author":"M Lenders","year":"2020","unstructured":"Lenders M, Boutin M, Auray-Blais C, Brand E. Effects of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease. Gastroenterology. 2020;159:1602\u20134.","journal-title":"Gastroenterology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01486-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:45:29Z","timestamp":1698021929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01486-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01486-1","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"23 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}